Clinical Trials

Carcinoma, Non-Small-Cell Lung

NCT03292133 2025-06-10

A Study of EGF816 and Gefitinib in TKI-naïve EGFR-mutant Non-Small Cell Lung Cancer

Phase 2 Terminated

11 enrolled 10 charts

Phase 2 Active not recruiting

Lung Neoplasms

NCT03944772 2025-01-30

ORCHARD

247 enrolled

Carcinoma, Non-Small-Cell Lung

NCT02347839 2024-12-10

NEGOTIATE

Phase 2 Withdrawn

Lung Neoplasms

NCT04322890 2024-10-22

PIKACHU

Phase 2 Recruiting

6,000 enrolled

Carcinoma, Non-Small-Cell Lung

NCT01833572 2023-07-12

Preoperative Gefitinib for EGFR Mutant II-IIIa NSCLC (ECTOP-1001)

36 enrolled

Carcinoma, Non-Small-Cell Lung

NCT02804776 2021-06-02

PROGRESS

15 enrolled

Carcinoma, Non-Small-Cell Lung

NCT01610336 2021-04-08

A Safety and Efficacy Study of INC280 and Gefitinib in Patients With EGFR Mutated, c-MET-amplified NSCLC Who Have Progressed After EGFRi Treatment

161 enrolled 32 charts

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT02025218 2021-04-01

IRENE

Phase 2 Terminated

21 enrolled

Lung Neoplasms

NCT01556191 2021-01-08

LADIE

379 enrolled

Lung Neoplasms

NCT03457337 2020-07-10

S-1 Plus Gefitinib Versus Gefitinib Monotherapy in Patients With EGFR-sensitive Mutation Advanced Non-squamous NSCLC

200 enrolled

Advanced NSCLC With EGFR Mutation

NCT04358562 2020-04-24

Gefitinib With Anlotinib in Advanced Non-squamous NSCLC Patients With Uncleared Plasma ctDNA EGFRm After First-line Treatment With Gefitinib

240 enrolled

Carcinoma, Non-Small-Cell Lung

NCT01466660 2020-04-07

LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung

319 enrolled 19 charts

Lung Neoplasms

NCT01933347 2020-02-06

Third-line Treatment of Gefitinib in NSCLC Patients

46 enrolled

Carcinoma, Non-Small-Cell Lung

NCT02976116 2019-11-15

A Phase II Study of Fruquintinib in Combination With Gefitinib in Patients With Advanced Non-small Cell Lung Cancer

50 enrolled

NSCLC

NCT01469000 2019-09-10

A Study of Pemetrexed and Gefitinib Versus Gefitinib in Non-Small Cell Lung Cancer (NSCLC)

195 enrolled 17 charts

Carcinoma, Non-Small-Cell Lung

NCT02179671 2019-08-02

Immune-Modulated Study of Selected Small Molecules (Gefitinib, AZD9291, or Selumetinib + Docetaxel) or a 1st Immune-Mediated Therapy (IMT; Tremelimumab) With a Sequential Switch to a 2nd IMT (MEDI4736) in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer

32 enrolled 11 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT01864681 2018-06-20

CGMT

224 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03486496 2018-04-03

Geber

50 enrolled

Adenocarcinoma of Lung

NCT03399669 2018-01-16

The Continuation of Gefitinib Treatment Beyond Progression in Non-small Cell Lung Cancer Patients With EGFR Mutation

100 enrolled

Carcinoma, Non-Small-Cell Lung

NCT00452244 2017-08-25

Gefitinib With or Without Simvastatin in Non-Small Cell Lung Cancer (NSCLC)

110 enrolled

Lung Neoplasms

NCT03123484 2017-04-21

β-elemene Combine With EGFR-TKI for Advanced EGFR-TKI-resistant NSCLC

80 enrolled

Carcinoma, Non-Small-Cell Lung

NCT00188617 2017-03-14

Phase 2 Study Of Neoadjuvant Iressa Treatment In Stage 1 NSCLC

35 enrolled

Lung Neoplasms

NCT00231465 2017-03-03

Phase II Study of Docetaxel + ZD1839 in Elderly Patients With Non-Small Cell Lung Cancer

44 enrolled 7 charts

Carcinoma, Non-Small-Cell Lung, Pleural Effusion, Malignant

NCT03002844 2016-12-28

EGFR-TKI With/Without Chemotherapy in NSCLC Patients With Both EGFR Mutation and BIM Deletion Polymorphism

50 enrolled

Carcinoma, Non-Small-Cell Lung

NCT00062062 2016-12-14

Gefitinib With or Without Carboplatin and Paclitaxel in Treating Older Patients With Unresectable or Metastatic Non-Small Cell Lung Cancer

65 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT02787447 2016-11-25

Radiotherapy Combined With Thymosin for Metastatic NSCLC Patients Who Showed Stable Disease After First Line TKI Therapy

46 enrolled

Adenocarcinoma of Lung

NCT02951637 2016-11-01

Chemotherapy Plus Gefitinib for Advanced Lung Adenocarcinoma and Sensitive EGFR Mutations: a Randomized Controlled Trial

300 enrolled

Adenocarcinoma of Lung, Adenocarcinoma

NCT02930954 2016-10-13

Gefitinib Combined With Chemotherapy or Antiangiogensis in Patients With Bim Deletion or Low EGFR Mutation Abundance

180 enrolled

Carcinoma, Non-Small-Cell Lung

NCT00059722 2016-08-24

This Study is to Compare the Efficacy of ZD6474 and ZD1839 in Subjects With NSCLC.

160 enrolled

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT01405846 2016-08-19

TIDAL1

Phase 2 Terminated

32 enrolled

Head & NeckThoracic

Head and Neck Neoplasms, Lung Neoplasms

NCT02788058 2016-06-02

A Study of Hypofractionated Radiotherapy for Limited Metastatic NSCLC Harboring Sensitizing EGFR Mutations After First Line TKI Therapy

76 enrolled

Adenocarcinoma of Lung

NCT01530334 2016-02-23

ICARUS

61 enrolled 11 charts

Lung Neoplasms

NCT01783834 2016-02-11

Gefitinib Versus Pemetrexed for Previously Treated NSCLC Patients

95 enrolled

Previous Treated Metastatic Non-small Cell Lung Cancer

NCT00588445 2016-01-22

Phase II Trial to Correlate Radiographic Response Induced By Gefitinib With Mutations in the Protein-Tyrosine Kinase Domain of the EGF Receptor Gene

65 enrolled 7 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms

NCT00986284 2015-12-22

Epidermal Growth Factor Receptor (EGFR) Status Based Gefitinib Neoadjuvant Therapy in Non Small Cell Lung Cancer (NSCLC)

Phase 2 Suspended

102 enrolled

Carcinoma, Non-Small-Cell Lung

NCT01955421 2015-07-03

NSCLC EGFR TKI

224 enrolled

Advanced Stage Non Small Cell Lung Cancer

NCT02319577 2014-12-18

GEfitinib Plus viNOrelbine in Advanced EGFR Mutated NSCLC. GENOA Trial

80 enrolled

Carcinoma, Non-Small-Cell Lung

NCT01498562 2014-12-02

DATE

160 enrolled

Carcinoma, Non-Small-Cell Lung

NCT01017679 2013-12-10

Gefitinib 500mg Versus 250mg in Patients With NSCLC With Stable Disease After a Month Treatment of Gefitinib 250mg

96 enrolled

Carcinoma, Non-Small-Cell Lung

NCT01024712 2013-08-12

Paclitaxel, Carboplatin, and Gefitinib in Treating Patients With Advanced Non-Small Cell Lung Cancer

26 enrolled

Adenocarcinoma of Lung, Adenocarcinoma, Bronchiolo-Alveolar, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00040794 2013-06-05

Combination Chemotherapy, Radiation Therapy, and Gefitinib in Treating Patients With Stage III Non-Small Cell Lung Cancer

144 enrolled

Adenocarcinoma of Lung, Adenocarcinoma, Bronchiolo-Alveolar, Carcinoma, Non-Small-Cell Lung

NCT00411047 2013-05-14

Gefitinib in Treating Patients With Previously Untreated Stage IIIB or Stage IV Non-Small Cell Lung Cancer

34 enrolled

Adenocarcinoma of Lung, Adenocarcinoma, Bronchiolo-Alveolar, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00068653 2013-04-29

Gefitinib and Celecoxib in Treating Patients With Refractory Non-Small Cell Lung Cancer

27 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00029003 2013-02-28

Gefitinib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

90 enrolled

Adenocarcinoma, Bronchiolo-Alveolar, Carcinoma, Non-Small-Cell Lung

NCT00824746 2013-02-26

ReGaiN

23 enrolled 9 charts

Carcinoma, Non-Small-Cell Lung, Recurrence

NCT01510990 2013-01-29

First Line Gefitinib by FDG-PET Metabolic Response

60 enrolled

Carcinoma, Non-Small-Cell Lung

NCT00025207 2013-01-17

Gefitinib in Treating Patients With Malignant Mesothelioma

Other solid neoplasmThoracic

40 enrolled

Mesothelioma, Malignant, Solitary Fibrous Tumor, Pleural

NCT01755923 2012-12-24

Gefitinib or Docetaxel as Second Line Therapy for Wild-type Epidermal Growth Factor Receptor (EGFR) NSCLC

60 enrolled

Carcinoma, Non-Small-Cell Lung

NCT01749072 2012-12-13

Vinorelbine-ifosfamide Versus Gefitinib for EGFR Gene Mutation Negative Non-small Cell Lung Cancer Patients

120 enrolled